Germany softens drug discount plan after industry backlash
Berlin backed away from a variable drug-discount formula after a lobbying fight that rattled Eli Lilly, Boehringer Ingelheim and others. Fixed rebates won out, easing fears over investment.
Berlin backed away from a proposal that would have forced drugmakers to give discounts that rose and fell with Germany’s overall pharmaceutical spending, a shift that had triggered a fierce backlash from industry and patient groups. The revised plan would set the rebates at a fixed level instead, giving companies a clearer view of future costs and revenues as lawmakers try to calm a healthcare system under mounting strain.
The retreat came as the broader reform package, first unveiled in April 2026 and later approved by the federal cabinet on April 29, aimed to close a funding gap of about 20 billion euros and prevent a rise in mandatory health-insurance premiums. Separate estimates said the statutory health insurance system, known as GKV, could otherwise face a 38.1 billion-euro shortfall in 2030. Pharma-related measures in the draft were expected to deliver about 1.9 billion euros in savings in 2027, making the drug discount plan one of the most important pieces of the financing puzzle.
Drugmakers had argued that a variable formula tied to the health system’s finances would make planning harder and chill investment in manufacturing and research. That pressure sharpened after Eli Lilly said on June 3 it would halve its planned 2.3 billion-euro investment in Germany. More than 1 billion euros had already gone into Lilly’s production site in Alzey, in Rhineland-Palatinate, but the plant was still scheduled to begin operations in 2027 at reduced capacity, with only half of the originally planned 1,000 jobs.
Lilly’s pullback was not isolated. Boehringer Ingelheim was also reported to be cutting about 900 million euros from planned German investment, a signal that the industry had moved from warning to retaliation. Roche took a different line, saying it would keep investing in Germany, including a 600-million-euro diagnostic production site in Penzberg. Pfizer chief executive Albert Bourla later warned Chancellor Friedrich Merz in a letter that the reforms threatened the predictability companies need for long-term investment.
Health minister Nina Warken’s camp did not publicly confirm that a final decision had been locked in, leaving the compromise inside parliamentary negotiations. Still, the direction was clear: Berlin was trying to squeeze savings out of a strained system without driving away the manufacturers that supply medicines, factories and skilled jobs. For patients, insurers and pharma alike, the fight showed how Europe’s largest economy was still struggling to balance affordability against the investment power that keeps new drugs and production lines coming.
This article was produced by Prism’s automated news system from verified source data, official records, and press releases, then run through automated quality and moderation checks before publishing. The system is built and supervised by the people who set the standards it runs under. Read our full AI policy.
Know something we missed? Have a correction or additional information?
Submit a Tip
